SEC Form 4 · accession 0001237899-18-000022
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard S Schleifer
Officer — President & CEO · Director
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2018 | M | 187,500 | $16.80 | A | 459,093 | D | |
| Common Stock | Dec 13, 2018 | F | 96,079 | $377.31 | D | 363,014 | D | |
| Common Stock | Dec 13, 2018 | M | 125,000 | $16.80 | A | 488,014 | D | |
| Common Stock | Dec 13, 2018 | F | 64,052 | $377.31 | D | 423,962 | D | |
| Common Stock | holding | — | — | — | 5,754 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $16.80 | Dec 13, 2018 | M | 187,500 | D | — | Dec 17, 2018 | Common Stock | 187,500 | 125,000 | D |
| Non-Qualified Stock Option (right to buy)F2 | $16.80 | Dec 13, 2018 | M | 125,000 | D | — | Dec 17, 2018 | Common Stock | 125,000 | 0 | D |
| Non-Qualified Stock Option (right to buy)F3 | $381.40 | Dec 12, 2018 | A | 129,013 | A | — | Dec 12, 2028 | Common Stock | 129,013 | 129,013 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2With respect to 187,500 underlying shares, the option became exercisable on December 31, 2011, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2011. With respect to 125,000 underlying shares, the stock option award vested in four equal annual installments, commencing one year after the date of grant.
- F3The stock option award vests in four equal annual installments, commencing one year after the date of grant.